Mesolimbic system and tardive dyskinesia: new perspectives for therapy.
D014150:Antipsychotic Agents / Q000494:pharmacology; D003342:Corpus Striatum / Q000187:drug effects / Q000503:physiopathology*; D004409:Dyskinesia, Drug-Induced / Q000503:physiopathology* / Q000517:prevention & control; D006801:Humans; D008032:Limbic System / Q000187:drug effects / Q000503:physiopathology*; D009434:Neural Pathways / Q000503:physiopathology; D010891:Piribedil / Q000627:therapeutic use; D011941:Receptors, Adrenergic / Q000502:physiology; D011954:Receptors, Dopamine / Q000187:drug effects / Q000502:physiology*; D013378:Substantia Nigra / Q000503:physiopathology
D014150:Antipsychotic Agents; D011941:Receptors, Adrenergic; D011954:Receptors, Dopamine; D010891:Piribedil